Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for genetically-defined rare diseases. Its lead product candidate is pociredir, being developed for conditions including sickle cell disease (SCD). The company does not own manufacturing facilities and relies on contract manufacturing organizations (CMOs) for clinical and commercial supply of its product candidates.
Q2 FY2026 — expected 2026-08-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-065197 | EDGAR | 88K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026068 | EDGAR | 92K words |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021074 | EDGAR | 95K words |
| 2023-03-09 | 2022-12-31 | 0000950170-23-006841 | EDGAR | 101K words |
| 2022-03-03 | 2021-12-31 | 0000950170-22-002727 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010715 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0001564590-20-008951 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-30 | 2026-06-30 | 0001193125-26-326098 | EDGAR | 53K words |
| 2025-10-29 | 2025-09-30 | 0001193125-25-254633 | EDGAR | 56K words |
| 2025-07-29 | 2025-06-30 | 0000950170-25-099407 | EDGAR | 55K words |
| 2025-05-01 | 2025-03-31 | 0000950170-25-061442 | EDGAR | 53K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-125931 | EDGAR | 60K words |
| 2024-07-31 | 2024-06-30 | 0000950170-24-088238 | EDGAR | 59K words |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058193 | EDGAR | 55K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059755 | EDGAR | 59K words |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037579 | EDGAR | 59K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021960 | EDGAR | 56K words |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022913 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016644 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-17 | 0001193125-26-353278 | EDGAR | 6K words |
| 2026-08-10 | 0001193125-26-341385 | EDGAR | 1K words |
| 2026-02-24 | 0001193125-26-065190 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-009845 | EDGAR | 4K words |
| 2025-12-11 | 0001193125-25-314728 | EDGAR | 1K words |
| 2025-12-08 | 0001193125-25-310509 | EDGAR | 2K words |
| 2025-10-29 | 0001193125-25-254619 | EDGAR | 2K words |
| 2025-08-28 | 0001193125-25-190746 | EDGAR | 4K words |
| 2025-07-29 | 0000950170-25-099404 | EDGAR | 2K words |
| 2025-06-27 | 0001193125-25-151276 | EDGAR | 1K words |
133 total filings indexed. 104 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001680581 |
| Ticker | FULC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.fulcrumtx.com |
| Listed | 2019-07-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/FULC (~200 tokens, structured JSON with cryptographic provenance)